Literature DB >> 30284039

ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients.

Yasmeen Razvi1, Stephanie Chan1, Thomas McFarlane1, Erin McKenzie1, Pearl Zaki1, Carlo DeAngelis1, William Pidduck1, Ahmad Bushehri1, Edward Chow1, Katarzyna Joanna Jerzak2,3.   

Abstract

Chemotherapy-induced nausea and vomiting (CINV) is a common toxicity that may impair the quality of life of patients with a variety of early- and end-stage malignancies. In light of recent changes in the optimal management of CINV, we undertook this narrative review to compare the latest guidelines published by ASCO (2017), NCCN (2018), and MASCC/ESMO (2016). The processes undertaken by each organization to evaluate existing literature were also described. Although ASCO, NCCN, and MASCC/ESMO guidelines for the treatment and prevention of CINV share many fundamental similarities, literature surrounding low and minimal emetic risk regimens is lacking. Data regarding the use of complementary alternative medicine for CINV is particularly scarce and in need of further investigation.

Entities:  

Keywords:  Antiemetic; Chemotherapy-induced nausea and vomiting; Guidelines; Prophylaxis

Mesh:

Substances:

Year:  2018        PMID: 30284039     DOI: 10.1007/s00520-018-4464-y

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  28 in total

1.  Direct provider feedback to decrease chemotherapy ordering errors: the "gray envelope" initiative.

Authors:  Katie Bruce; Laura Hall; Sarah Castelo; Misty Evans; Haydar Frangoul
Journal:  Pediatr Blood Cancer       Date:  2012-06-12       Impact factor: 3.167

2.  Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.

Authors:  Rudolph M Navari; Rui Qin; Kathryn J Ruddy; Heshan Liu; Steven F Powell; Madhuri Bajaj; Leah Dietrich; David Biggs; Jacqueline M Lafky; Charles L Loprinzi
Journal:  N Engl J Med       Date:  2016-07-14       Impact factor: 91.245

Review 3.  Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update.

Authors:  Paul J Hesketh; Mark G Kris; Ethan Basch; Kari Bohlke; Sally Y Barbour; Rebecca Anne Clark-Snow; Michael A Danso; Kristopher Dennis; L Lee Dupuis; Stacie B Dusetzina; Cathy Eng; Petra C Feyer; Karin Jordan; Kimberly Noonan; Dee Sparacio; Mark R Somerfield; Gary H Lyman
Journal:  J Clin Oncol       Date:  2017-07-31       Impact factor: 44.544

4.  Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.

Authors:  F Roila; B Ruggeri; E Ballatori; S Fatigoni; C Caserta; L Licitra; A Mirabile; M T Ionta; B Massidda; L Cavanna; M A Palladino; A Tocci; S Fava; I Colantonio; L Angelelli; L Ciuffreda; G Fasola; F Zerilli
Journal:  Ann Oncol       Date:  2015-03-05       Impact factor: 32.976

5.  Efficacy of acupuncture in prevention of delayed chemotherapy induced nausea and vomiting in gynecologic cancer patients.

Authors:  Kulthida Rithirangsriroj; Tarinee Manchana; Lanchasak Akkayagorn
Journal:  Gynecol Oncol       Date:  2014-10-31       Impact factor: 5.482

6.  Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study.

Authors:  Fausto Roila; Benedetta Ruggeri; Enzo Ballatori; Albano Del Favero; Maurizio Tonato
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

7.  The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.

Authors:  Rudolph M Navari; Cindy K Nagy; Sarah E Gray
Journal:  Support Care Cancer       Date:  2013-01-12       Impact factor: 3.603

8.  A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.

Authors:  M Aapro; H Rugo; G Rossi; G Rizzi; M E Borroni; I Bondarenko; T Sarosiek; C Oprean; S Cardona-Huerta; V Lorusso; M Karthaus; L Schwartzberg; S Grunberg
Journal:  Ann Oncol       Date:  2014-03-05       Impact factor: 32.976

9.  Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use.

Authors:  Steven A Pergam; Maresa C Woodfield; Christine M Lee; Guang-Shing Cheng; Kelsey K Baker; Sara R Marquis; Jesse R Fann
Journal:  Cancer       Date:  2017-09-25       Impact factor: 6.860

10.  Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.

Authors:  C Weinstein; K Jordan; S A Green; E Camacho; S Khanani; E Beckford-Brathwaite; W Vallejos; L W Liang; S J Noga; B L Rapoport
Journal:  Ann Oncol       Date:  2015-10-08       Impact factor: 32.976

View more
  24 in total

1.  Emergency Department Visits for Emesis Following Chemotherapy: Guideline Nonadherence, OP-35, and a Path Back to the Future.

Authors:  Alfred I Neugut; Susan E Bates
Journal:  Oncologist       Date:  2021-03-04

Review 2.  Antiemetic drugs: what to prescribe and when.

Authors:  Akshay Athavale; Tegan Athavale; Darren M Roberts
Journal:  Aust Prescr       Date:  2020-04-01

Review 3.  Do Patients Benefit from a Trial of Corticosteroids at the End of Life?

Authors:  Sriram Yennurajalingam; Eduardo Bruera
Journal:  Curr Treat Options Oncol       Date:  2022-04-01

4.  Is area under the curve the best parameter for carboplatin induced emetic risk stratification?

Authors:  Sachiko Ozone; Kazuya Ichikawa; Masahiro Morise; Akira Matsui; Fumie Kinoshita; Reiko Matsuzawa; Junji Koyama; Ichidai Tanaka; Naozumi Hashimoto
Journal:  Nagoya J Med Sci       Date:  2021-11       Impact factor: 1.131

Review 5.  Premedications for Cancer Therapies: A Primer for the Hematology/Oncology Provider.

Authors:  Amber Clemmons; Arpita Gandhi; Andrea Clarke; Sarah Jimenez; Thuy Le; Germame Ajebo
Journal:  J Adv Pract Oncol       Date:  2021-11-01

6.  Malus domestica reduces chemotherapy-induced nausea and vomiting: A randomized double-blind placebo-controlled clinical trial.

Authors:  Sharareh Darvishpour; Razieh Avan; Mohammad Azadbakht; Monireh Maham; Jafar Akbari; Ghasem Janbabaei; Ehsan Zaboli; Ali Reza Amirabadizadeh; Ebrahim Salehifar
Journal:  J Res Med Sci       Date:  2021-09-30       Impact factor: 1.852

7.  Reduction of the Vertebral Bone Mineral Density in Patients with Hodgkin Lymphoma Correlates with Their Age and the Treatment Regimen They Received.

Authors:  Nadav Ofshenko; Eyal Bercovich; Tania Mashiach; Michal Weiler-Sagie; Daniela Militianu; Eldad J Dann
Journal:  Cancers (Basel)       Date:  2022-01-19       Impact factor: 6.639

8.  A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation.

Authors:  Shannon D Armbruster; Bryan M Fellman; Anuja Jhingran; Patricia J Eifel; Ann H Klopp; Robert L Coleman; Lois M Ramondetta; Michael Frumovitz
Journal:  Support Care Cancer       Date:  2020-04-27       Impact factor: 3.603

Review 9.  Strategies to Mitigate Chemotherapy and Radiation Toxicities That Affect Eating.

Authors:  Peter M Anderson; Stefanie M Thomas; Shauna Sartoski; Jacob G Scott; Kaitlin Sobilo; Sara Bewley; Laura K Salvador; Maritza Salazar-Abshire
Journal:  Nutrients       Date:  2021-12-08       Impact factor: 5.717

Review 10.  The Safety of Dronabinol and Nabilone: A Systematic Review and Meta-Analysis of Clinical Trials.

Authors:  Ákos Bajtel; Tivadar Kiss; Barbara Tóth; Szabolcs Kiss; Péter Hegyi; Nóra Vörhendi; Boglárka Csupor-Löffler; Noémi Gede; Judit Hohmann; Dezső Csupor
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.